沙库巴曲缬沙坦钠片联合通心络胶囊在AMI患者PCI术后中的应用  

Application of Sacubitril/Valsartan sodium tablets combined with Tongxinluo capsules in patients after PCI for acute myocardial infarction

作　　者：李萍 王新 李臻 Li Ping;Wang Xin;Li Zhen(Department of Cardiovascular Medicine,Xi'an Hospital of Traditional Chinese Medicine,Xi'an 710000,China;Interventional Department,Xi'an Hospital of Traditional Chinese Medicine,Xi'an 710000,China)

机构地区：[1]西安市中医医院心血管内科,西安710000 [2]西安市中医医院介入科,西安710000

出　　处：《国际医药卫生导报》2024年第20期3438-3442,共5页International Medicine and Health Guidance News

基　　金：陕西省自然科学基础研究计划(2022JQ-978)。

摘　　要：目的探讨沙库巴曲缬沙坦钠片联合通心络胶囊在急性心肌梗死(AMI)患者经皮冠状动脉介入(PCI)术后中的应用价值。方法选取2021年11月至2023年10月在西安市中医医院行PCI治疗的194例AMI患者作为研究对象。通过电脑编码,将患者随机分为对照组(97例)和联合组(97例)。对照组男56例,女41例;年龄36~74(55.83±8.42)岁;PCI术后1~6(3.49±0.63)h。联合组男53例,女44例;年龄36~75(55.87±8.46)岁;PCI术后1~6(3.53±0.58)h。对照组采用常规治疗联合沙库巴曲缬沙坦钠片口服治疗,联合组在对照组基础上采用通心络胶囊口服治疗。两组均治疗8周,治疗后随访6个月。比较两组治疗前后心肌梗死溶栓试验(TIMI)血流分级、心功能[左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)]和炎症因子水平[超敏C反应蛋白(hs-CRP)和白细胞介素(IL)-6],随访期间主要不良心血管事件(MACE)发生情况。采用独立样本t检验、配对t检验、秩和检验和χ^(2)检验。结果治疗后,联合组TIMI血流分级优于对照组(P<0.05);联合组LVESD[(32.44±4.29)mm]、LVEDD[(40.35±4.92)mm]均低于对照组[(38.64±4.82)mm、(47.82±5.73)mm],LVEF[(65.83±5.78)%]高于对照组[(58.36±5.36)%](均P<0.05);联合组hs-CRP[(3.11±1.28)mg/L]、IL-6[(12.43±3.27)ng/L]水平均低于对照组[(6.84±1.93)mg/L、(15.68±3.94)ng/L](均P<0.05)。随访期间,联合组MACE总发生率[12.37%(12/97)]低于对照组[26.80%(26/97)](P<0.05)。结论沙库巴曲缬沙坦钠片与通心络胶囊联合使用可改善AMI患者PCI术后心功能和炎症因子水平,降低MACE总发生率。Objective To investigate the application value of Sacubitril/Valsartan sodium tablets combined with Tongxinluo capsules in patients after percutaneous coronary intervention(PCI)for acute myocardial infarction(AMI).Methods A total of 194 AMI patients who underwent PCI at Xi'an Hospital of Traditional Chinese Medicine from November 2021 to October 2023 were selected for the study objects.They were randomly divided into a control group(97 cases)and a combined group(97 cases)using computer coding method.In the control group,there were 56 males and 41 females,aged 36-74(55.83±8.42)years,1-6(3.49±0.63)h after PCI.There were 53 males and 44 females in the combined group,aged 36-75(55.87±8.46)years,1-6(3.53±0.58)h after PCI.The control group was treated with Sacubitril/Valsartan sodium tablets combined with conventional treatment,while the combined group additionally received Tongxinluo capsules.After 8 weeks of treatment,they were followed up for 6 months.The blood flow grading of thrombolysis in myocardial infarction(TIMI),cardiac function[left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),and left ventricular ejection fraction(LVEF)]and levels of inflammatory factors[hypersensitive C-reactive protein(hs-CRP)and interleukin(IL)-6]before and after treatment,and incidence of major adverse cardiovascular events(MACE)during follow-up were compared between the two groups.Independent sample t test,paired t test,rank sum test,andχ^(2) test were used.Results After treatment,the TIMI blood flow grading in the combined group was better than that in the control group(P<0.05).After treatment,the LVESD[(32.44±4.29)mm]and LVEDD[(40.35±4.92)mm]in the combined group were lower than those in the control group[(38.64±4.82)mm and(47.82±5.73)mm],and the LVEF[(65.83±5.78)%]was higher than that in the control group[(58.36±5.36)%](all P<0.05);the levels of hs-CRP[(3.11±1.28)mg/L]and IL-6[(12.43±3.27)ng/L]in the combined group were lower than those in the control group[(6.84±1.93)mg/L an

关 键 词：急性心肌梗死 经皮冠状动脉介入 沙库巴曲缬沙坦钠片 通心络胶囊 

分 类 号：R542.22[医药卫生—心血管疾病]